Clinical Trials for Phase I Trials

12 Open Trials

Trial Type &
Disease
Protocol No. &
Open Date
Summary
Treatment
Breast;
Colon;
Lung;
Ovarian;
Pancreatic;
Prostate;
Rectal
VICCPHI1394
04/17/2014
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
TreatmentVICCPHI1364
03/07/2014
A Phase Ib, Open-Label Study of Oral BGJ398 in Combination with Oral BYL719 in Adult Patients with Select Advanced Solid Tumors
TreatmentVICCPHI1342
02/11/2014
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
TreatmentVICCPHI1255
09/28/2013
Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
TreatmentVICCPHI1327
07/29/2013
A Phase 1, Open-Label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
Treatment
Prostate
VICCURO1260
03/19/2013
A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy
Treatment
Breast
VICCPHI1248
10/12/2012
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Treatment
Pancreatic
VICCGI1173
07/31/2012
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma
TreatmentVICCTHN1244
07/25/2012
Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors
TreatmentVICCPHI1065
02/01/2011
A phase IA, multicenter, open-label dose escalation study of oral BYL719, in adult patients with advanced solid malignancies, whose tumors have an alteration of the PIK3CA gene
Treatment
Hematologic/Non-transplant
VICCPHI1040
12/21/2010
A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy
Treatment
GIST
VICCPHI0958
02/05/2010
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology

You do not have JavaScript enabled. This site works better with JavaScript turned on.